Malin Corporation | MLC - Betriebsaufwand

Aktienkurs
7.60
Täglich Wechseln
0 0%
Monatlich
-5.00%
Jährlich
-10.59%
Q2 Prognose
7.76




Betriebsaufwand Veränderung Datum
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alaunos Therapeutics USD 1.19M 148K 2025-09
ALKERMES USD 1.75B 1.43B 2026-03
Avita Medical AUD 28.02M 1.55M 2025-12
Dianthus Therapeutics USD 69.82M 29.14M 2025-12
Eurofins Scientific SE EUR 3.29B 462.3M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
IQVIA Holdings USD 6.22B 4.53B 2026-03
Lonza CHF 2.9B 184M 2025-06
Malin Corporation EUR 1.1M 400K 2024-12
Moderna USD 1.78B 242M 2026-03
Organon & Co USD 903M 387M 2026-03
Ovoca Bio EUR 1.16M 4.48M 2025-06
Revvity USD 628.34M 2.12M 2026-03
Tectonic Therapeutic USD 21.52M 374K 2025-12
Viatris USD 3.54B 323.9M 2026-03
Xeris Pharmaceuticals USD 69.03M 1.38M 2025-12